Artizan Biosciences Inc. reported Friday afternoon a $5 million offering of private securities, according to a filing with the Securities and Exchange Commission.

Of the total offering amount, Artizan raised $3 million within the first 15 days of the offering. Five investors contributed. It has $2 million remaining to raise.

Available to purchase was a combination of equity, along with either an option, warrant or other right to acquire another security, as well as any securities subsequently made available by exercising an acquired security.

The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as it current revenue range.

The company provides pharmaceutical drug development services, namely, development of small molecule drugs for use in humans.